Major Pharma Got a Major Win Last Night - BMO

November 9, 2016 7:54 AM EST
Get Alerts ABBV Hot Sheet
Price: $61.54 +1.05%

Rating Summary:
    10 Buy, 12 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade ABBV Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

BMO Capital analyst Alex Arfaei said a Trump presidency, Republican controlled congress, and apparent defeat of CA Prop 61 as significantly positive developments for major Pharma because they should lead to:

1) lower drug pricing pressure in the U.S.,

2) potential repeal of Obamacare with more industry friendly reforms,

3) increased probability for lower corporate tax rates, and profit repatriation, which should in turn lead to increased capital returned to shareholders and more M&A.

"We see the news as positive for our entire coverage universe, particularly for PFE (NYSE: PFE)," he said.

Other Stocks:

AbbVie (NYSE: ABBV)
Bristol-Myers Squibb (NYSE: BMY)
Kindred Biosciences (NASDAQ: KIN)
Eli Lilly & Co. (NYSE: LLY)
Merck (NYSE: MRK)
Zoetis (NYSE: ZTS)



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Hot Comments, Trader Talk

Related Entities

BMO Capital

Add Your Comment